The Koch Institute for Integrative Cancer Research at MIT, a National Cancer Institute (NCI)-designated cancer center, has announced that Tyler Jacks will step down from his role as director, pending selection of his successor.
“An exceptionally creative scientist and a leader of great vision, Tyler also has a rare gift for launching and managing large, complex organizations, attracting exceptional talent and inspiring philanthropic support,” says MIT President L. Rafael Reif. “We are profoundly grateful for all the ways he has served MIT, including most recently his leadership on the Research Ramp Up Lightning Committee, which made it possible for MIT’s research enterprise to resume in safe ways after the initial Covid shutdown. I offer warmest admiration and best wishes as Tyler steps down from leading the Koch and returns full time to the excitement of the lab.”
Jacks, the David H. Koch Professor of Biology, has served as director for more than 19 years, first for the MIT Center for Cancer Research (CCR) and then for its successor, the Koch Institute. The CCR was founded by Nobel laureate Salvador Luria in 1974, shortly after the federal government declared “war on cancer,” with the mission of unravelling the molecular core of cancer. Jacks became the center’s fourth director in 2001, following Luria, Nobel laureate and Institute Professor Phillip Sharp, and Daniel K. Ludwig Professor for Cancer Research Richard Hynes.
Aided by the championship of then-MIT President Susan Hockfield and a gift of $100 million from MIT alumnus David H. Koch ’62, SM ’63, Jacks oversaw the evolution of the Center for Cancer Research into the Koch Institute in 2007 as well as the construction of a new home in Building 76, completed in 2010. The Koch Institute expands the mission of its predecessor by bringing life scientists and engineers together to advance understanding of the basic biology of cancer, and to develop new tools to better diagnose, monitor, and treat the disease.
Under the direction of Jacks, the institute has become an engine of collaborative cancer research at MIT. “Tyler’s vision and execution of a convergent cancer research program has propelled the Koch Institute to the forefront of discovery,” notes Maria Zuber, MIT’s vice president for research.
Bolstered by the Koch Institute’s associate directors Jacqueline Lees, Matthew Vander Heiden, Darrell Irvine, and Dane Wittrup, Jacks oversaw four successful renewals of the coveted NCI-designated cancer center stature, with the last two renewals garnering perfect scores. In 2015, Jacks was the recipient of the James R. Killian Jr. Faculty Achievement Award, the highest honor the MIT faculty can bestow upon one of its members, for his leadership in cancer research and for his role in establishing the Koch Institute.
“Tyler Jacks turned the compelling idea to accelerate progress against cancer by bringing together fundamental biology, engineering know-how, and clinical expertise, into the intensively collaborative environment that is now the Koch Institute for Integrative Cancer Research,” says Hockfield. “His extraordinary leadership has amplified the original idea into a paradigm-changing approach to cancer, which now serves as a model for research centers around the world.”
To support cross-disciplinary research in high-impact areas and expedite translation from the bench to the clinic, Jacks and his colleagues shepherded the creation of numerous centers and programs, among them the Ludwig Center for Molecular Oncology, the Marble Center for Cancer Nanomedicine, the MIT Center for Precision Cancer Medicine, the Swanson Biotechnology Center, the Lustgarten Lab for Pancreatic Cancer Research, and the MIT Stem Cell Initiative. In addition, Jacks has co-led the Bridge Project, a collaboration between the Koch Institute and Dana-Farber/Harvard Cancer Center that brings bioengineers, cancer scientists, and clinical oncologists together to solve some of the most challenging problems in cancer research. Jacks has raised nearly $375 million in support of these efforts, as well as the building of the Koch Institute facility, the Koch Institute Frontier Research Program, and other activities.
Jacks first became interested in cancer as a Harvard University undergraduate while attending a lecture by Robert Weinberg, the Daniel K. Ludwig Professor of Cancer Research and member of the Whitehead Institute, who is himself a pioneer in cancer genetics. After earning his PhD at the University of California at San Francisco under the direction of Nobel laureate Harold Varmus, Jacks joined Weinberg’s lab as a postdoctoral fellow. He joined the MIT faculty in 1992 with appointments in the Center for Cancer Research and the Department of Biology.
Jacks is widely considered a leader in the development of engineered mouse models of human cancers, and has pioneered the use of gene-targeting technology to construct mouse models and to study cancer-associated genes in mice. Strains of mice developed in his lab are used by researchers around the world, as well as by neighboring labs within the Koch Institute. Because these models closely resemble human forms of the disease, they have allowed researchers to track how tumors progress and to test new ways to detect and treat cancer. In more recent research, Jacks has been using mouse models to investigate how immune and tumor cells interact during cancer development and how tumors successfully evade immune recognition. This research is expected to lead to new immune-based therapies for human cancer.
Outside his research and MIT leadership, Jacks co-chaired the Blue Ribbon Panel for the National Cancer Moonshot Initiative, chaired the National Cancer Advisory Board of the National Cancer Institute, and is a past president of the American Association for Cancer Research. He is an elected member of the National Academy of Science, the National Academy of Medicine and the American Academy of Arts and Sciences. Jacks serves on the Board of Directors of Amgen and Thermo Fisher Scientific. He is also a co-founder of T2 Biosystems and Dragonfly Therapeutics, serves as an advisor to several other companies, and is a member of the Harvard Board of Overseers.
Sharp will lead the search for the next director of the Koch Institute, with guidance from noted leaders in MIT’s cancer research community, including Hockfield and Hynes, as well as Angela M. Belcher, head of the Department of Biological Engineering and Jason Mason Crafts Professor; Paula T. Hammond, head of the Department of Chemical Engineering and David H. Koch Professor of Engineering; Amy Keating, professor of biology; Robert S. Langer, David H. Koch Institute Professor; and David M. Sabatini, Professor of Biology and member, Whitehead Institute for Biomedical Research.
“Jacks is a renowned scientist whose personal research has changed the prevention and treatment of cancer,” says Sharp. “His contributions to the creation of the Koch Institute for Integrative Cancer Research and his leadership as its inaugural director have also transformed cancer research at MIT and nationally. By integrating engineers and cancer biologists into a community that shares knowledge and skills, and collaborates with clinical scientists and the private sector, this convergent institute represents the future of biological research in the MIT style.”
After Jacks steps down, he will continue his research in the areas of cancer genetics and immune-oncology and his teaching, while also stewarding the Bridge Project into its second decade.
“It has been a privilege for me to serve as director of the MIT Center for Cancer Research and the Koch Institute for the past two decades and to work alongside many of the brightest minds in cancer research,” says Jacks. “The Koch Institute is a powerhouse of research and innovation, and I look forward to the next generation of leadership in this very special place.”
Electronic skin has a strong future stretching ahead
A material that mimics human skin in ?strength, stretchability and sensitivity could be used to collect biological data in real time. Electronic skin, or e-skin, may play an important role in next-generation prosthetics, personalized medicine, soft robotics and artificial intelligence.
“The ideal e-skin will mimic the many natural functions of human skin, such as sensing temperature and touch, accurately and in real time,” says KAUST postdoc Yichen Cai. However, making suitably flexible electronics that can perform such delicate tasks while also enduring the bumps and scrapes of everyday life is challenging, and each material involved must be carefully engineered.
Most e-skins are made by layering an active nanomaterial (the sensor) on a stretchy surface that attaches to human skin. However, the connection between these layers is often too weak, which reduces the durability and sensitivity of the material; alternatively, if it is too strong, flexibility becomes limited, making it more likely to crack and break the circuit.
“The landscape of skin electronics keeps shifting at a spectacular pace,” says Cai. “The emergence of 2D sensors has accelerated efforts to integrate these atomically thin, mechanically strong materials into functional, durable artificial skins.”
A team led by Cai and colleague Jie Shen has now created a durable e-skin using a hydrogel reinforced with silica nanoparticles as a strong and stretchy substrate and a 2D titanium carbide MXene as the sensing layer, bound together with highly conductive nanowires.
“Hydrogels are more than 70 percent water, making them very compatible with human skin tissues,” explains Shen. By prestretching the hydrogel in all directions, applying a layer of nanowires, and then carefully controlling its release, the researchers created conductive pathways to the sensor layer that remained intact even when the material was stretched to 28 times its original size.
Their prototype e-skin could sense objects from 20 centimeters away, respond to stimuli in less than one tenth of a second, and when used as a pressure sensor, could distinguish handwriting written upon it. It continued to work well after 5,000 deformations, recovering in about a quarter of a second each time. “It is a striking achievement for an e-skin to maintain toughness after repeated use,” says Shen, “which mimics the elasticity and rapid recovery of human skin.”
Such e-skins could monitor a range of biological information, such as changes in blood pressure, which can be detected from vibrations in the arteries to movements of large limbs and joints. This data can then be shared and stored on the cloud via Wi-Fi.
“One remaining obstacle to the widespread use of e-skins lies in scaling up of high-resolution sensors,” adds group leader Vincent Tung; “however, laser-assisted additive manufacturing offers new promise.”
“We envisage a future for this technology beyond biology,” adds Cai. “Stretchable sensor tape could one day monitor the structural health of inanimate objects, such as furniture and aircraft.”
German researchers compile world’s largest inventory of known plant species
Leipzig could mean for the future of plant taxonomy what Greenwich meant for world time until 1972: it could become the reference city for correct scientific plant names. In an outstanding feat of research, the curator of the Botanical Garden of Leipzig University, Dr Martin Freiberg, and colleagues from iDiv and UL have compiled what is now the largest and most complete list of scientific names of all known plant species in the world. The Leipzig Catalogue of Vascular Plants (LCVP) enormously updates and expands existing knowledge on the naming of plant species, and could replace The Plant List (TPL) – a catalogue created by the Royal Botanic Gardens, Kew in London which until now has been the most important reference source for plant researchers.
“In my daily work at the Botanical Garden, I regularly come across species names that are not clear, where existing reference lists have gaps,” said Freiberg. “This always means additional research, which keeps you from doing your actual work and above all limits the reliability of research findings. I wanted to eliminate this obstacle as well as possible.”
World’s most comprehensive and reliable catalogue of plant names
With 1,315,562 scientific names, the LCVP is the largest of its kind in the world describing vascular plants. Freiberg compiled information from accessible relevant databases, harmonized it and standardised the names listed according to the best possible criteria. On the basis of 4500 other studies, he investigated further discrepancies such as different spellings and synonyms. He also added thousands of new species to the existing lists – species identified in recent years, mainly thanks to rapid advances in molecular genetic analysis techniques.
The LCVP now comprises 351,180 vascular plant species and 6160 natural hybrids across 13,460 genera, 564 families and 84 orders. It also lists all synonyms and provides further taxonomic details. This means that it contains over 70,000 more species and subspecies than the most important reference work to date, TPL. The latter has not been updated since 2013, making it an increasingly outdated tool for use in research, according to Freiberg.
“The catalogue will help considerably in ensuring that researchers all over the world refer to the same species when they use a name,” says Freiberg. Originally, he had intended his data set for internal use in Leipzig. “But then many colleagues from other botanical gardens in Germany urged me to make the work available to everyone.”
LCVP vastly expands global knowledge of plant diversity
“Almost every field in plant research depends on reliably naming species,” says Dr Marten Winter of iDiv, adding: “Modern science often means combining data sets from different sources. We need to know exactly which species people refer to, so as not to compare apples and oranges or to erroneously lump different species.” Using the LCVP as a reference will now offer researchers a much higher degree of certainty and reduce confusion. And this will also increase the reliability of research results, adds Winter.
“Working alone, Martin Freiberg has achieved something truly incredible here,” says the director of the Botanical Garden and co-author Prof Christian Wirth (UL, iDiv). “This work has been a mammoth task, and with the LCVP he has rendered an invaluable service to plant research worldwide. I am also pleased that our colleagues from iDiv, with their expertise in biodiversity informatics, were able to make a significant contribution to this work.”
This research was in part supported by the DFG – Deutsche Forschungsgemeinschaft (FZT-118).
Benefits of Purchasing Used Lab Equipment
In the laboratory industry, there can be a lot of pressure to always have the newest and latest technology. Due to concerns about having outdated or inefficient equipment, many professionals don’t even consider purchasing used equipment. However, there are numerous advantages to doing so. Here are some of the key benefits of purchasing used lab equipment to keep in mind next time you need to purchase equipment.
One of the most significant and obvious benefits of purchasing used lab equipment is that doing so can save you a lot of money. Used laboratory equipment is significantly less expensive than brand new models. Often laboratories can save up to 50 percent or more by purchasing quality second-hand equipment.
Because laboratory equipment is often one of the top expenses that laboratories incur, purchasing used can substantially reduce laboratory costs and free up some much-needed room in tight budgets.
Large laboratory equipment can take up a lot of room in landfills and often contain toxic components such as lead or mercury. Such toxins can seep into the earth and contaminate groundwater over time. By purchasing used laboratory equipment rather than new, you can reduce the amount of equipment that ends up in landfills. Plus, you will also reduce the number of raw materials used to manufacture new equipment which will decrease your lab’s negative impact on the environment.
Purchasing a new type of equipment right after it is released comes with some risks. When a piece of equipment is fresh on the market, there aren’t many reviews from past customers attesting to how well or poorly it operates.\
Used equipment, however, is far less risky. Because the equipment has been on the market for a while, there are likely plenty of reviews that you can reference and any potential issues have likely been well-documented. Just make sure to purchase from a reliable and trustworthy reseller that took the proper measures to ensure the equipment is in optimal operating condition.
Reduced Wait Time
If you need a piece of equipment in a short period of time, buying used is often the best option. Many manufacturers have long wait times that can require you to wait for several weeks or even months before the equipment will arrive. If you have deadlines you need to meet, that simply won’t do. In cases when you need equipment in a timelier manner, used equipment is already built and ready to go so you often only have to wait for shipping.
Source: Christina Duron is a freelance writer for multiple online publications where she can showcase her affinity for all things digital. She has focused her career around digital marketing and writes to explore topics that spark her interest.
CYIOS CORP’S RECEIVES APPROVAL TO SELL ITS SANITIZER PRODUCTS ON AMAZON.COM
Deerfield Beach, Florida, November 23, 2020 – OTC PR WIRE — CYIOS Corp. (OTC US: CYIO), a publicly traded company focused on developing and marketing specialty branded products in the Health and Wellness markets, is pleased to announce it has received approval from Amazon to sell various My-shield sanitizing products in Amazon’s Personal Safety and Household category. Products to be sold on Amazon.com will include the My-shield triple play sanitizing products which have recently undergone clinical studies for effectiveness including My Shield Hand Sanitizer, My-shield Surface Cleaner and My-shield Laundry Complete. Clinical data from these studies conducted on this trio of My-shield sanitizing products have shown long lasting sanitizer protection and effectiveness against a surrogate virus for SARS-CoV-2 on skin, hard surfaces, fabrics and clothes.
John O’Shea CYIO’s Chairman stated, “We are pleased to have received this approval to sell various My-shield sanitizing products in Amazon’s Personal Safety and Household category. Our strategy continues to be on developing market and distribution opportunities around a Triple Play of sanitizing products which have recently undergone clinical studies for effectiveness including My Shield Hand Sanitizer, My-shield Surface Cleaner and My-shield Laundry Complete. During the six week period of time we had to undergo for the approval process within this product category, several of the My-shield Zetrisl® based sanitizer products had completed lengthy clinical testing in a laboratory setting and showed effectiveness against a CDC recognized surrogate virus for SARS-CoV-2 on skin, hard surfaces, fabrics and clothes. Results of which are posted here: Zetrisil-The-Total-Covid-19-Solution
Approval on Amazon gives the Company an additional platform for selling direct to consumers, which complements our recently announced launch with RangeMe giving us direct access to thousands of retail purchasing managers on their B2B platform. As we enter the holiday season, keep an eye out for valuable holiday specials, product marketing and advertising on the My-shield Triple Play and our “24” Brand Hand sanitizer which is also Zetrisl® powered. We believe giving the gift of safety and security with these long-lasting clinically proven sanitizers for effectiveness is a terrific and thoughtful holiday gift”.
About Zetrisil: Zetrisil®-based technologies are a family of proprietary silicon-based virus killing agents that reduce the presence of the virus from the hands, hard surfaces, fabric and most clothing environments. Zetrisil® effectively protects and/or “shields” the area that “24” Brand hand sanitizer and My-shield products are applied to from bacterial contamination for an extended period of time after application. Made with non-alcohol, Benzalkonium Chloride (BZK), My-shield® and 24 Brand sanitizers are a safer alternative to Alcohol-based hand sanitizers which can be absorbed into the bloodstream, are flammable, and are only proven effective for a few minutes after each application. These factors make traditional alcohol-based hand sanitizers a less than optimal choice particularly for families with children and/or for those out and about in public. Because Zetrisil® is safer than traditional agents and remains on the skin for several hours, people are protected longer without the need for frequent applications of sanitizer ― all without the toxicity and flammability concerns of alcohol-based sanitizers. The recent clinical testing data is powerful and proven evidence of the effectiveness of these products.
Investors are encouraged to follow CYIOS using:
About ChoiceWellness, Inc:
ChoiceWellness, Inc. is a health and wellness company that has brought to market the DR’s CHOICE line of products, as well as the “24” Brand Hand Sanitizer products. DR’s CHOICE was developed with a mission to offer Doctors and Medical Practitioners their own Professional Grade CBD BRAND with a suite of products they could stand behind and be confident to offer to their patients. Our customers can be assured that DR’s CHOICE CBD products have gone through the highest scrutiny of testing for purity, potency and quality. DR’s Choice products have been brought to market for Doctors and Medical Professionals seeking a better solution for patients suffering from pain, inflammation, anxiety or other persistent symptoms. For more information please visit www.choicewellnessbrands.com
About CYIOS Corporation
CYIOS Corporation is a publicly traded company focused on developing and marketing specialty branded products in the Health and Wellness markets, including the “DR’s CHOICE” and “24” brand of products. The team has in-depth knowledge of the health and wellness markets, financial services industry, medical and health services, and blockchain. The Company looks to develop, distribute, and license proprietary products as well as evaluate potential acquisition opportunities. Further, the Company continues to seek and evaluate attractive business opportunities and to leverage its resources and expertise to build a diversified, sustainable business model. For more information please visit www.cyioscorporation.com
FORWARD-LOOKING STATEMENTS: This release contains “forward-looking statements.” Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management’s current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified by the use of words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “would,” “could,” “will” & other words of similar meaning in connection with a discussion of future operating or financial performance. Examples of forward-looking statements include, among others, statements relating to future sales, earnings, cash flows, results of operations, uses of cash and other measures of financial performance. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and other factors that may cause the Company’s actual results and financial condition to differ materially from those expressed or implied in the forward-looking statements. Such risks, uncertainties and other factors include, among others such as, but not limited to economic conditions, changes in the laws or regulations, demand for products and services of the company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward-looking statements. Any forward-looking information provided in this release should be considered w/ these factors in mind. We assume no obligation to update any forward-looking statements contained in this report.
An ionic forcefield for nanoparticles: Tunable coating allows hitch-hiking nanoparticles to slip past the immune system to their target
Allay Their Fears WoW: How to Complete the Quest
The Rock Expresses Interest in Fortnite Skin Modeled on Him
Doublelift Retires: A Tale of Glory, Downfall, and Legacy
Native Fortnite Locations: How to Complete the Challenge
One-way street for electrons: Scientists observe directed energy transport between neighbouring molecules in a nanomaterial
Quantum nanodiamonds may help detect disease earlier: The quantum sensing abilities of nanodiamonds can be used to improve the sensitivity of paper-based diagnostic tests, potentially allowing for earlier detection of diseases such as HIV, according to a study led by UCL research
Phytoplankton disturbed by nanoparticles: Due to its antibacterial properties, nanosilver is used in a wide range of products from textiles to cosmetics; but nanosilver if present at high concentrations also disrupts the metabolism of algae that are essential for the aquatic food
Russian scientists improve 3D printing technology for aerospace composites using oil waste
Pitt researchers create nanoscale slalom course for electrons: Professors from the Department of Physics and Astronomy have created a serpentine path for electrons
Original Content podcast: Just don’t watch Netflix’s ‘Holidate’ with your parents
XRI Launches Survey Examining Diversity & Inclusion Within XR Industry
Malta’s Pivots to Becoming a Fintech Haven
Black Friday on track for $8.9B+ in online sales as shoppers stay away from brick-and-mortar stores
Blockchain Voting is Possible: Dispelling Myths & Fears
Chinese Banks Suspend New Gold Trading Accounts Creation Amid Price Slump
Tony Hsieh, iconic Las Vegas tech entrepreneur, dies aged 46
NANO Rejected but Could Attempt Another Breakout Soon
How do Safe Online Sportsbooks Protect your Data?
OKEx Introduces One of Crypto’s Largest Loyalty Rewards Programs
Zoomlion begeistert auf der bauma China 2020 mit intelligenten Baumaschinen der nächsten Generation und sichert sich Aufträge im Wert von über 3 Milliarden USD
Ripple Is Cashing Out a Third of Its Stake in Surging MoneyGram
DreamHack Open November reaches playoffs
Zoomlion impressiona na Exposição bauma China 2020 com o lançamento de maquinários de construção inteligentes de última geração garantindo mais de US$ 3 bilhões em pedidos
mousesports move on to BLAST Premier Fall Showdown semis over Heroic
Zoomlion cautiva en la exposición bauma China 2020 con el lanzamiento de maquinaria de construcción inteligente de próxima generación que asegura más de 3 mil millones de dólares en pedidos
Insights on the Fatty Alcohol Global Market to 2026 – Featuring BASF, Ecogreen Oleochemicals & Godrej Industries Among Others
The Chemours Company Announces Completion of Private Offering of $800 Million Aggregate Principal Amount of 5.750% Senior Unsecured Notes Due 2028
Insights into Global High Voltage Switchgear Industries and Manufacturers to 2030 – by Equipment Type, Type of Use, Voltage Range and Customer Type
Zoomlion impressionne lors de la bauma China 2020 avec le lancement de machines de construction intelligentes de nouvelle génération lui permettant d’obtenir des commandes de plus de 3 G$
Energy6 days ago
ADAMA Mourns Death of Joe Krkoska, Executive Vice President of Global Operations
Blockchain1 week ago
Ethereum on a Tear as It Breaks New Yearly High
Blockchain1 week ago
Ethereum 2.0 Sees $10 Million Stake from Dubai-Based Investment Firm
Cyber Security1 week ago
Where Machine Learning Is Transforming Finance
Blockchain1 week ago
Bitcoin Begins to Stall After Parabolic Ascent
Blockchain1 week ago
Deutsche Bank Says Investors Increasingly Prefer Bitcoin Over Gold as Inflation Hedge
Blockchain4 days ago
Ethereum Becomes One of the Largest Proof of Stake Chains Even Before Launch
Energy6 days ago
Firmy Shanghai Electric a Siemens Energy založí Centrum na podporu rozvoje chytré energetiky (Smart Energy Empowerment Center)